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Abstract
As the reality of pandemic threats challenges humanity, exemplified during the ongoing SARS-CoV-2 infections, the development of vaccines targeting these etiological agents of disease has become increasingly critical. Of paramount concern are novel
and reemerging pathogens that could trigger such events, including the plague bacterium Yersinia pestis. Y. pestis is responsible
for more human deaths than any other known pathogen and exists globally in endemic regions of the world, including the four
corners region and Northern California in the USA. Recent cases have been scattered throughout the world, including China and
the USA, with serious outbreaks in Madagascar during 2008, 2013–2014, and, most recently, 2017–2018. This review will focus
on recent advances in plague vaccine development, a seemingly necessary endeavor, as there is no Food and Drug
Administration–licensed vaccine available for human distribution in western nations, and that antibiotic-resistant strains are
recovered clinically or intentionally developed. Progress and recent development involving subunit, live-attenuated, and nucleic
acid–based plague vaccine candidates will be discussed in this review.
Key points
• Plague vaccine development remains elusive yet critical.
• DNA, animal, and live-attenuated vaccine candidates gain traction.
Keywords Live attenuated . DNA vaccines . Protein subunit . Humoral . Protection

Introduction
Of all Yersinia species (spp.), three are pathogenic to humans:
Y. enterocolitica, Y. pseudotuberculosis, and Y. pestis
(Rosenzweig et al. 2011; Rosenzweig and Chopra 2012).
The two former species typically cause self-limiting gastroenteritis, often referred to as yersiniosis, although
Y. enterocolitica is more commonly associated with the disease (Galindo et al. 2011). Y. pestis, by contrast, is a bona fide
highly invasive human pathogen, the stuff [sic] of nightmares.
Although only having evolutionarily diverged from
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Y. pseudotuberculosis some 1500–20,000 years ago
(Achtman et al. 1999), Y. pestis causes three forms of human
disease: bubonic (often promoting fulminant infection), septicemic, and pneumonic with high morbidity and mortality rates
(approaching 100%) if left untreated (Titball and Leary 1998;
Demeure et al. 2019a, b). More specifically, plague-induced
mortality has claimed over 200 million human lives during the
course of 3 major human pandemics ranging from 541 CE
(Justinian plague) through the 1300s (Black Death plague)
until today (Indo-China plague) (Rosenzweig et al. 2011;
Sun 2016; Sun and Singh 2019; Williamson 2009). The cumulative, historical death-toll serves as a grim reminder of our
extreme vulnerability. Raising global concerns, the most recent outbreak in Madagascar (2017–2018) resulted in 202
deaths (from 2348 cases, with ~76% of the cases being pneumonic) during a 3-month period (WHO Plague-Madgascar
n.d.).
Genetically distinguishable from its two related gastrointestinal Yersinia spp., Y. pestis gained a subset of genes,
enhancing survival in both flea and mouse/rat reservoirs,
as well as lost subsets of its chromosome, including adhesin
encoding genes used for gut epithelium attachment
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(Achtman et al. 1999; Demeure et al. 2019a, b). Y. pestis is
typically transmitted via the bite of an arthropod vector, the
flea, and persists in rodent populations. Unfortunately,
humans occasionally interrupt the vector-rodent chain of
transmission resulting in grave consequences (Greenfield
et al. 2002; Rosenzweig et al. 2011; Rosenzweig and
Chopra 2012).

Type three secretion system injectosome and type six
secretion system
All three pathogenic yersiniae possess a 70-kb virulence
plasmid that encodes a type three secretion system (T3SS),
an evolutionarily repurposed flagellar, macromolecular
complex/system (Abby and Rocha 2012). The 70-kb virulence plasmid, termed pCD1 in Y. pestis, piB1 in
Y. pseudotuberculosis, or pYV in Y. enterocolitica, encodes
the requisite machinery for the hyper-structure T3SS
injectosome as well as its potent anti-host effector proteins/
toxins (Cornelis et al. 1998). Multiple hyper-structures, including the T3SS, exist within yersiniae. Moreover, these
hyper-structures or their components likely interact. For example, the RNA degradosome, a macromolecular hyperstructure involved in RNA decay and processing
(Carpousis 2007), is believed to cooperate with the T3SS
within yersiniae (Norris et al. 2012; Yang et al. 2008;
Rosenzweig et al. 2005; Rosenzweig et al. 2007).
Twenty-seven Yersinia secretion proteins (Yscs) comprise
the T3SS injectosome, and the substrates secreted through the
Ysc needle conduit are termed Yersinia outer membrane proteins (Yops). There are 6 effector Yops, each exerting its own
anti-host property, while the remaining Yops serve deliveryfacilitating roles, including the low calcium response V
(LcrV) antigen (Miletic et al. 2020; Demeure et al. 2019a, b;
Grabowski et al. 2017; Trosky et al. 2008; Cornelis 2003). In
addition to the T3SS, the type 2 secretion system (T2SS) of
Y. enterocolitica has also been shown to support its virulence
by promoting tissue invasion (von Tils et al. 2012).
Beyond the T2SS and the T3SS, a T6SS has been
characterized in all three pathogenic yersiniae (Yang
et al. 2018). The T6SS is evolutionarily derived from
repurposed phage machinery, enabling bacteria to puncture
target cells and subsequently deliver effector proteins
(Zoued et al. 2014). Y. pestis was found to possess 5
T6SS encoding clusters of virulence-associated secretion
genes (vas) (Andersson et al. 2017; Li et al. 2015).
Interestingly, 3 of the 5 T6SS clusters were required for
full virulence in murine models of infection (Ponnusamy
et al. 2015). None of the T6SS antigens has yet been
targeted as vaccine development candidates, although they
represent potential candidates (Ponnusamy et al. 2015,
Fitts et al., 2016, and Andersson et al. 2017).
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Vaccine targets beyond the T3SS: other Y. pestis
plasmids and their gene products
The plague pathogen is benefitted by having additional virulence factors extending beyond its T3SS injectosome.
Although the 70-kb virulence plasmid is shared by all three
pathogenic yersiniae, only Y. pestis possesses two additional
plasmids: the 9.5-kb pPCP1 plasmid (pPla) and the 110-kb
pMT1 plasmid (pFra). The pPCP1 plasmid encodes the
plasminogen-activating protease (Pla), which promotes bacterial dissemination via disruptions in blot clot formation and
complement cascade activation (Suomalainen et al. 2007).
Additionally, a pPla plasmid addiction system encoding a
bacteriocin, pesticin, and its immunity gene product, pesticin
immunity protein, ensures both selection pressure on plasmid
maintenance and an offensive strategy that kills bacterial
neighbors lacking the immunity protein (Rosenzweig et al.
2011 and references therein).
The pMT1 plasmid encodes a highly immunogenic, antiphagocytic capsular antigen Fraction 1, referred to as F1. Due
to its ability to induce robust immune responses, the F1 antigen has been the subject of a large number of plague candidate
vaccine development efforts (Williamson and Oyston 2013;
Rosenzweig et al. 2011; Demeure et al. 2019a, b; Sun and
Singh 2019). Additionally, the plasmid encodes the 61-kDa
Yersinia murine toxin (Ymt) known to promote bacterial survival in the flea mid-gut, and purified Ymt has been shown to
promote broad toxicity in mice, including decreased blood
sugar levels and internal bleeding (Fan et al. 2016).
Although Ymt is required for mid-gut colonization of
Y. pestis in the flea 1–2 weeks following infection, Ymt is
not required for early-phase transmission (3 days postinfection) from flea to mouse (Johnson et al. 2014). As plague
vaccine development gains momentum and traction, new candidate vaccines (Tables 1 and 2) are being evaluated for their
safety and efficacy with the hope of several achieving clinical
trial status in the near future.

Subunit vaccine strategies
Major subunit plague vaccine candidates are utilizing F1 and
LcrV antigens, prompting the development of recombinant
F1-LcrV (rF1-V) vaccines (Rosenzweig et al. 2011).
However, there have been shortcomings with rF1-V candidates necessitating modifications so as to elicit more robust
cellular immune responses (Smiley 2008). Consequently, a
CD137 ligand was included as an adjuvant together with
alhydrogel in the rF1-V vaccine platform, and was demonstrated to induce enhanced cell-mediated immunity (Bowen
et al. 2019). Unfortunately, enhanced cell-mediated immunity
in male mice did not translate into protection when animals
were primed and boosted with the rF1-V + alhydrogel +
CD137 ligand vaccine candidate in a pneumonic plague
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Table 1
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Y. pestis protein subunit and DNA vaccine candidates

Vaccine

Animal model

Efficacy

Reference

Protein subunit
rF1-V + CD137 ligand+ alhydrogel

Mouse

Enhanced CMI; no protection against pneumonic challenge

Bowen et al.
2019

Micro-vesicle (Bacteroides spp.) F1-V

Nonhuman
primates

Robust IgA and IgG in blood and airways

Carvalho
et al. 2019

Lyophilized F1 LcrV (stored 29 weeks at
40°C)

Balb/c mice

Protection against bubonic plague

Moore et al.
2018

F1-loaded microspheres [F1-Al(OH)3)]

Blab/c mice

100% protection against bubonic plague; robust IgG

Huang et al.
2014

F1 rV

100% sero-conversion high IgG titers

Hu et al. 2018

Single-dose F1-V-loaded polyanhydride
nanoparticle coupled with cyclic dinucleotides
F1-V + Myd88+ TLR4

Humans (18-55
year olds)
Mouse

Short-term and long-term humoral immunity; protection
against pneumonic plague

Wagner et al.
2019

Mouse

Protection against pneumonic plague

Dankmeyer
et al. 2014

LcrV + F1 + B. anthracis PA and LF

Mouse

100% protection against pneumonic plague; 90% protection against
anthrax toxin

Gallagher
et al. 2019

OmpA, Ail, and Pla

Mouse

OmpA and Ail protected against bubonic plague; Pla protected against Erova et al.
pneumonic plague
2013

DNA
LcrV-F1 and B. anthracis PA (electroporation system)

AJ mice

Balanced Th1/Th2 response; 100% protection against lethal plague and Albrecht et al.
lethal B. anthracis spore challenge
2012a

LcrV-F1 and truncated B. anthracis PA
(gene gun delivery system)

AJ mice

Enhanced survival against pneumonic plague when boosted with a
DNA vaccine encoding the B. anthracis PA

Albrecht et al.
2012b

LcrV DNA vaccine prime and LcrV
protein subunit vaccine boost

Balb/c mice

High antibody titers of anti-LcrV antibodies

Li et al. 2014

model; only female mice were protected against pneumonic
plague for unknown reasons (Bowen et al. 2019). In a novel
approach, Carvalho et al. (2019) have employed microvesicles derived from recombinant commensal Bacteroides
spp. expressing and producing plague F1 and LcrV antigens
as a vaccine delivery platform. This system allowed for facile
targeted delivery of plague antigen–charged micro-vesicles to
both lung and gut mucosa of nonhuman primates resulting in
robust IgG and IgA production in blood and airways, respectively (Carvalho et al. 2019).
Storage and ensuring integrity are of paramount concerns,
particularly when shipping vaccines to various parts of the
world where refrigeration may be unavailable. With that in
mind, a dual subunit vaccine consisting of associated F1 and
LcrV was lyophilized. Not only was the preparation stable for
29 weeks at 40°C, but subcutaneous administration and an
orally delivered boost also protected immunized Balb/c mice
from bubonic challenge (Moore et al. 2018). In a similar approach, F1-loaded microspheres were characterized for their
antigen release kinetics in vitro as well as for their immunogenicity in a murine model. Not only was a robust anti-F1 IgG
titer measured but also 100% protection in Balb/c mice was

achieved following a prime-boost regimen (Huang et al.
2014).
Interestingly, in a Chinese human clinical study evaluating
an F1 + rV vaccine candidate, not only was the vaccine well
tolerated in 18–55-year-olds but also it generated significant
antibody titers and 100% sero-conversion for F1 antibodies
(Hu et al. 2018). Additionally, single doses of an F1-V-loaded
polyanhydride nanoparticle vaccine, when coupled with cyclic dinucleotides capable of inducing interferon genes, induced both rapid short-term and long-term humoral immunity
in mice that protected against pneumonic plague (Wagner
et al. 2019). Eliminating a boost requirement makes this candidate an attractive option. In attempting to elucidate the F1-V
vaccine-induced host signaling responses in mice, the myeloid
differentiation primary response 88 protein (MyD88) and
Toll-like receptor (TLR)-4, but not TLR-2, were required for
optimal vaccine immune response as well as subsequent protection against pneumonic plague challenge (Dankmeyer et al.
2014).
In some instances, plague subunit vaccines have included
proteins from other bacterial pathogens creating cocktail subunit vaccine candidates (Rosenzweig et al. 2011). A multiple
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Y. pestis recombinant, live-attenuated, and rodent vaccine candidates

Vaccine

Animal model

Recombinant
Dual PA anthrax-LcrV-F1 plague nanoparti- Mice rats and
cle T4 phage delivery system
rabbits
Y. pseudotuberculosis expressing the Y. pestis Mice
F1 antigen
Oral Y. pseudotuberculosis ΔyopK ΔyopJ
Δasd + Y. pestis fusion protein (truncated
YopE1-138-LcrV

Mouse

Y. pestis KIM ΔyopJ overexpressing the
Y. enterocolitica YopP

OF1 mice

Lactobacillus plantarum expressing LvrV-F1 Mouse
and Tobacco Mosaic Virus (TMV) expressing LcrV-F1
Salmonella expressing LcrV, F1 and pesticin Mouse
receptor (Psn)
Francisella tularensis ΔcapB + F1-LcrV and Mouse
a multiple-gene-deleted Listeria
monocytogenes vaccine strain, + F1-LcrV
Live-attenuated vaccines
EV vaccine efficacy measure
Humans
(Kazakhstan)
EV plague vaccine strain

Humans

Y. pestis subspecies: altaica 1-2948/3, 1-3749, Mouse
and 1/3480
Y. pestis EV vaccine strain and the microtus
201 (avirulent in humans) strain

Efficacy

Reference

Complete protection against both lethal challenges of
inhalation anthrax and pneumonic plague
Protection against both bubonic and pneumonic
challenge, and serum transfer to naïve mice protected
against bubonic challenge; protection against challenge
with F1 variant
Conferred 80% and 90% survival against bubonic and
pneumonic challenge; strong humoral and CMI
responses; protection against lethal Y. enterocolitica
and Y. pseudotuberculosis challenge
Protection against pneumonic and bubonic challenge and
against Y. enterocolitica challenge and Francisella
tularensis challenge
TMV LcrV-F1 provided 100% protection against a
pneumonic plague challenge; L. plantarum LcrV-F1
conferred only partial protection
Oral immunization, conferred 100% protection against
both bubonic and pneumonic plague

Tao et al. 2018

Following a prime-boost schedule with both platforms,
mice were protected against pneumonic plague challenge

Demeure et al. 2017,
2019a, b

Singh et al. 2019

Zauberman et al.
2013
Arnaboldi et al.
2016
Sananpala et al.
2016
Jia et al. 2018

Highest level of protective anti-F1 serum antibodies was Sagiyev et al. 2019
observed 4 months following vaccination with significant reduced antibody titers at both 8 and 12 months
Robust cell-mediated responses to Pla protease in immu- Feodorova et al.
nized humans for up to 1 year following vaccination
2018
Elicit strong cell-mediated responses

Balakhonov et al.
2017

Rhesus macaques
The microtus strain infected monkey lungs and led to
(intravenous (i.v.)
100% mortality in 1010 i.v.-challenged animals; none
infection model)
of the EV-challenged animals died at that same dose

Tian et al. 2014

Rodent
Sylvatic plague vaccine (SPV), a virally
vectored bait system vaccine

Wild prairie dogs

Rocke et al. 2017

SPV

Wild prairie dogs

SPV

Wild prairie dogs

SPV

Wild prairie dogs
and non-target
rodents
Mice and rats

LMA and LMP live-attenuated vaccines

Capture of unique prairie dogs on vaccine-treated fields
was significantly higher in each of the 2 years tested on
29 paired plots of land in 7 Western US states years
tested
Bait uptake of the SPV vaccine, during a 3-year study,
was as high as 70% over 58 plots of land; heavier
animals exhibited increased bait uptake; baiting later in
the growing season influenced bait uptake
In two of the three plots evaluated, both pesticide dusting
and oral SPV improved prairie dog survival
70% of the bait-based vaccine was consumed by
non-target rodents over a 3-year period in which no
effects were observed
100% efficacy during bubonic and pneumonic plague
(short- and ling-term), generate robust humoral and
cell-mediated immune responses

antigen fusion protein consisting of the Y. pestis LcrV and F1
antigens, as well as the Bacillus anthracis protective antigen
and lethal factor, was used to immunize and boost mice prior
to Y. pestis and anthrax toxin challenges. Encouragingly,

Abbott et al. 2018

Trip et al. 2017
Bron et al. 2018

Tiner et al. 2015a, b,
2016; Van Lier
et al. 2014, 2015

immunized mice were completely protected (i.e., 100%)
against subsequent Y. pestis challenge and 90% protected
against anthrax toxin (Gallagher et al. 2019). Some efforts
have cast a wider net and are interrogating other antigens as
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potential vaccine candidates. The attachment invasion locus
(Ail/OmpX), outer membrane protein A (OmpA), and Pla are
three such candidates. In mice, OmpA and Ail vaccines were
protective against bubonic challenge with an F1− Y. pestis
variant while the Pla candidate vaccine was protective against
pneumonic plague (Erova et al. 2013).

DNA vaccines
Oligonucleotide vaccine platforms offer several advantages
and have been gaining some traction over the years.
Criticism has emphasized poor immunogenicity; however,
the early success of the Pfizer and Moderna mRNA SARSCoV-2 vaccines may renew interest in oligonucleotide plague
vaccine development. Some plague DNA vaccine development has been highlighted in the literature (Rosenzweig
et al. 2011; Verma and Tuteja 2016 and references therein);
however, there have been a paucity of current advances.
In a report, plasmid constructs encoding two codonoptimized plague antigens, F1 and LcrV, together with the
protective antigen (PA) from B. anthracis, were used to develop DNA vaccine candidates; constructs were delivered to
mice using an electroporation-based system following a
prime-boost schedule. Not only were the pVAX constructs
encoding F1 and LcrV 100% protective in A/J inbred mice
following plague challenge but also the pVAX construct
encoding PA conferred 100% protection against a lethal
B. anthracis spore challenge (Albrecht et al. 2012). Most importantly, the aforementioned DNA vaccine candidates promoted a balanced Th1/Th2 response as evidenced by elevated
levels of both interferon-γ and interleukin-4 (Albrecht et al.
2012a). Such a response profile is certainly more desirable
than the Th2-skewed response profiles of many protein subunit vaccines. Similarly, a gene gun delivery of a DNA vaccine encoding a fusion of B. anthracis truncated lethal factor
protein and Y. pestis LcrV or F1 enhanced survival of mice
against pneumonic plague when boosted with a DNA vaccine
encoding the B. anthracis PA (Albrecht et al. 2012b).
Interestingly, DNA vaccines coupled with subunit boost
may work synergistically to acquire the greatest protection.
More specially, following immunization with a DNA vaccine
encoding LcrV and subsequent protein LcrV subunit vaccine
boost, high titers of anti-LcrV antibodies were measured in
Balb/c mice (Li et al. 2014; Wang et al. 2004).

Recombinant vaccines
Y. pestis and B. anthracis are the two most likely candidate
bacterial pathogens that could be weaponized for bio-warfare
(Rosenzweig et al. 2011). Therefore, some approaches combine the two, or derivatives thereof, into a single vaccine platform. Previously, a combined vaccine was protective in both a
mouse and rabbit model of bubonic plague and cutaneous
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anthrax (Ren et al. 2009). More recently, a dual anthraxplague nanoparticle that employed a T4 phage delivery system
was evaluated for efficacy. The anthrax-protective antigen and
the plague F1 and LcrV antigens were fused to phage T4 outer
capsid proteins. Encouragingly, the vaccine conferred complete protection against both lethal challenges of inhalation
anthrax and pneumonic plague in mice, rats, and rabbits
(Tao et al. 2018).
In another approach involving the use of recombinant
Y. pseudotuberculosis expressing the Y. pestis F1 antigen
(referred to as the VTnF1 vaccine candidate; Derbise et al.
2015), protection against bubonic and pneumonic challenge
was observed in both inbred and outbred murine models.
Furthermore, serum transfer to naïve mice demonstrated protection against bubonic challenge (Demeure et al. 2019a, b).
Following a single oral dose of VTnF1, mice were protected
against bubonic and pneumonic plague including challenge
with a Y. pestis variant devoid of the F1 antigen (Demeure
et al. 2017). This is a very attractive feature as Y. pestis strains
have been found to be lacking F1 in nature and are as virulent
as encapsulated strains.
On account of the absence of F1 in some Y. pestis strains,
several pipeline vaccine candidates have pivoted away from
F1. For example, an attenuated Y. pseudotuberculosis ΔyopK
ΔyopJ Δasd triple mutant, unable to produce the translocator
YopK and effector YopJ proteins, ectopically expressed a
Y. pestis fusion protein composed of a truncated YopE1-138LcrV. The candidate vaccine conferred 80% and 90% survival
following bubonic and pneumonic challenge, respectively, in
mice having received a single-dose oral immunization. Strong
humoral and cell-mediated responses were also observed with
protection against lethal Y. enterocolitica and
Y. pseudotuberculosis challenge (Singh et al. 2019). Still other
Y. pestis attenuated strains are being evaluated as potential
recombinant vaccine candidates, including the KIM strain.
More specifically, the KIM background strain was used to
generate a ΔyopJ mutant overexpressing the
Y. enterocolitica YopP; the recombinant Y. pestis vaccine candidate was able to protect Oncins France 1 (OF1), albino,
outbred mice against pneumonic and bubonic challenge via
host interferon-γ involvement. Surprisingly, the vaccine candidate was also able to protect against subsequent
Y. enterocolitica challenge. Interestingly, after infecting mice
with a subcutaneous dose of 1 × 104 cfu of the recombinant
Y. pestis KIM strain, ~70% of the mice were protected against
subsequent intranasal challenge with either 500 or 5000 cfu of
Francisella tularensis, an unrelated organism (Zauberman
et al. 2013). This peripheral benefit is due to the vaccine candidate eliciting cross-protective antibodies against
F. tularensis (Zauberman et al. 2013).
Some recent recombinant platforms have involved organisms other than yersiniae. A recombinant Lactobacillus
plantarum and a recombinant Tobacco Mosaic Virus
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(TMV), both expressing LcrV-F1, were employed in a mouse
immunization study. Only TMV expressing LcrV and F1
protected 100% of pneumonic plague–challenged mice, while
the L. plantarum LcrV-F1 expressing recombinant conferred
only partial protection as measured by mouse mortality
(Arnaboldi et al. 2016). Another strong candidate is a wellcharacterized Salmonella recombinant vaccine that was
engineered to express 3 plague antigens: a truncated LcrV,
F1, and pesticin receptor (Psn). Following oral immunization
using the aforementioned vaccine candidate, mice were 100%
protected against both bubonic and pneumonic plague
(Sananpala et al. 2016).
Additionally, a live vaccine strain for Francisella
tularensis devoid of its capB gene and an attenuated
multiple-gene-deleted Listeria monocytogenes vaccine strain,
both expressing F1-V plague recombinant protective antigens,
were evaluated. Following a prime-boost schedule with both
platforms, mice were protected against pneumonic plague
challenge (Jia et al. 2018). With fear of potential reversion, a
low-probable reality when considering a live-attenuated
Y. pestis vaccine or a recombinant Y. pseudotuberculosis,
Salmonella Typhimurium, F. tularensis, or
L. monocytogenes vaccine may offer a potentially safer alternative without compromising efficacy.

Adenovirus vector vaccines
While some strains of Y. pestis lack the F1 capsular antigen,
evidence has shown that these strains can be fully virulent
(Sha et al. 2011; Quenee et al. 2008). In addition, divergence
of LcrV variants presents issues for efficacy of F1-V vaccines.
Therefore, efforts have been focused on discovering combinations of immunogenic antigens that will provide protection
against these strains. Vaccination of mice with YscF, a T3SS
needle structure protein, showed increased protection against
intravenous (via the retro-orbital sinus) challenge with the
KIM5 strain (Matson et al. 2005). Based on this evidence, a
trivalent vaccine utilizing an adenovirus vector has shown
promise. Sha et al. (2016) employed a replication-defective
human type-5 adenovirus (Ad5) vector to construct a recombinant YFV fusion gene vaccine encompassing ycsF, caf1,
and lcrV. Impressively, one intranasal dose of the trivalent
rAD5-YFV vaccine combined with an intramuscular primeboost of recombinant fusion protein rYFV provided up to
100% protection in murine and nonhuman primate (NHP)
models when challenged with a high aerosol dose of CO92.
Furthermore, histopathological studies revealed vaccinated
NHPs showed no signs of lesions in various organ tissues
(Sha et al. 2016).
The World Health Organization (WHO) has since released
a target product profile for plague vaccines that includes recommendations for needle-free vaccines in 2 or fewer doses
(WHO Workshop 2018). In response to this recommendation,
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the rAd5-YFV vaccine was further evaluated using 1 or 2
intranasal doses without the rYFV prime-boost strategy. It
was shown that 2 doses provided 100% protection in both
pneumonic and bubonic plague models, as well as an induction of humoral, mucosal, and cell-mediated immunity
(Kilgore et al. 2021). Importantly, the vaccine was equally
(100%) protective in mice when challenge occurred with either the parental Y. pestis CO92 strain or its F1-negative variant (Kilgore et al., 2021). However, most humans likely possess pre-existing antibodies against Ad5, so immunogenicity
of Ad5-vectored vaccines could be low as a result. Both Sha
et al. (2016) and Kilgore et al. (2021) demonstrated that intranasal administration of the rAd5-YFV vaccine has the potential to bypass pre-existing antibodies to Ad5 vectors.
Furthermore, the Ad5 vector, when compared to other
adenovirus-vectored vaccines, elicits minimal proinflammatory responses (Teigler et al. 2012). As with the most recent
SARS-CoV-2 vaccines distributed by Johnson & Johnson
and AstraZeneca, adenovirus-vectored vaccines can be successfully implemented against high-consequence pathogens.

Live-attenuated vaccines
Until the recent advent of attenuated Y. pestis genetically mutated strains, the Western world has generally frowned upon
the utilization of a live-attenuated plague vaccine for widespread distribution (Sun et al. 2011; Wang et al. 2013).
Although the live-attenuated plague vaccine EV76, created
in 1936 in the Former Soviet Union, is still used by some
former Soviet countries, the vaccine is not utilized in the
USA, Europe, or Canada due to its strong reactogenicity
(Titball and Williamson 2004). Even so, millions of people
have received the live-attenuated EV76 vaccine in the past 80
years with minimal and ephemeral side effects (Feodorova
et al. 2014).
In fact, a protocol was developed to rapidly assess liveattenuated EV vaccine candidates in bubonic plague infection
models of both mice and guinea pigs (Feodorova et al. 2016).
Furthermore, to evaluate plague EV vaccine efficacy more
specifically, Sagiyev et al. (2019) measured anti-F1 antibody
titers to determine the undefined period of protection and
make future vaccine dosing schedule recommendations in
Kazakhstan. The highest level of protective anti-F1 serum
antibodies was observed 4 months following vaccination with
significant reductions in antibody titers at both 8 and 12
months following vaccination. As a result, recommendations
were made to vaccinate approximately 4 months ahead of
spring when rodent populations become active in
Kazakhstan (Sagiyev et al. 2019). To further evaluate the
EV plague vaccine strain, the cell-mediated responses to Pla
protease were measured in immunized humans and found to
be robust up to 1 year post-vaccination (Feodorova et al.
2018).
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Several other seemingly useful live-attenuated vaccine candidates with varying plasmid compositions have also
emerged. Y. pestis subspecies altaica 1-2948/3, 1-3749, and
1/3480 were able to elicit strong cell-mediated responses in a
mouse model of infection (Balakhonov et al. 2017). In that
same vein, a direct comparison of the virulence of the Y. pestis
EV vaccine strain to the microtus 201 (avirulent in humans)
strain in an intravenous (i.v.) rhesus macaque infection model
revealed that both strains were well tolerated in NHPs at high
doses. However, the microtus strain infected the lungs and led
to 100% mortality in 1010 i.v.-challenged animals; none of the
EV-challenged animals died at that same dose (Tian et al.
2014). The side effects associated with the EV strain in
humans as well as the ability of the pigmentation locus
(pgm) minus strains of Y. pestis to cause a fatal disease in
patients with hemochromatosis suggest that the EV mutant
strain could be further attenuated through specific gene knockouts to generate live-attenuated plague vaccine candidates, as
has been recently reported (Tiner et al. 2015A&B; Tiner et al.
2016; van Lier et al. 2014).
Another target for live-attenuated vaccine candidates has
been LPS and its derivatives. In Y. enterocolitica, the acetyltransferase, encoded by the msbB gene, was upregulated at
21°C, relative to the mammalian temperature of 37°C, leading
predominantly to a hexa-acylated lipid A as compared to predominantly tetra-acylated lipid A at 37°C. Furthermore, lipid
A acylation status was shown to directly affect virulenceassociated gene expression levels as well as sensitivity to
polymyxin B (Pérez-Gutiérrez et al. 2010). Additionally,
when the Escherichia coli–derived acyltransferase LpxL was
expressed in Y. pestis at 37°C, an atypical hexa-acylated lipid
A was observed, thereby promoting dendritic cell migration,
which was mollified by Y. pestis disruption of TLR-4induction of IL-12 (Robinson et al. 2008). Finally, by using
humanized mice expressing TLR-4, Y. pestis was shown to
use its thermal regulation of lipid A acylation states to evade
recognition by human TLR-4 (Hajjar et al. 2012). In that vein,
our group characterized the role of chromosomally encoded
Braun lipoprotein (Lpp) and the MsbB acetyltransferase in the
virulence of Y. pestis CO92. While Lpp activates TLR-2,
MsbB catalyzes the addition of lauric acid to the lipid A moiety of LPS, thus increasing its biological potency by activating
TLR-4 (Sha et al. 2013).
We demonstrated that combinatorial mutants (e.g.,
ΔlppΔmsbB/ail [LMA] and ΔlppΔmsbBΔpla [LMP]) were
more significantly attenuated (100% animal survival) than
single or double mutants, provided long-term protective immunity (cell-mediated and humoral) in rodents, and, thus,
could provide a platform for developing an efficacious liveattenuated plague vaccine(s) (Tiner et al. 2015A&B; Tiner
et al. 2016; van Lier et al. 2014; van Lier et al. 2015). The
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vaccine strains cleared from animals within 24 h with no histopathological lesions in various organs during immunization
or after challenge of immunized animals (Tier et al. 2015B,
Tiner et al. 2016; van Lier et al. 2014). These vaccine candidates provide protection against both bubonic and pneumonic
plague. Our vaccine strains have the following advantages: (1)
rationally designed with complete deletion of three genes, (2)
are stable with no risk for reversion because of the deletion of
three genes located on different DNA regions; the mutants
have been sequenced with no secondary mutations, (3) lpp
and msbB deletions greatly reduce host reactogenicity relative
to EV76 vaccine, (4) LMA/LMP mutants generate immune
responses to thousands of Yp antigens, thus would provide
cross-protection against different Yp biovars/strains, (5) the
mutants are excluded from the CDC select agent list, and (6)
fulfill the target product profile provided by the WHO.

Rodent vaccinations
Another approach to tackling the plague threat is to directly
vaccinate rodent zoonotic reservoirs. The major goal of such
efforts is conservation of delicate ecosystem balances by
protecting rodents susceptible to plague-induced mortality
(Salkeld 2017; Roth 2019). Furthermore, by such control,
plague infection spillover into human populations as collateral
damage can also be prevented (Richgels et al. 2016). Despite
the obvious challenges, including poor vaccine uptake and
unintended targets, several groups have taken this approach.
In an ambitious 2-year study, 29 paired plots of land seeded
with either a sylvatic plague vaccine (SPV), a virally vectored
bait system vaccine, or a placebo were compared in 7 Western
states in the USA. The capture of unique prairie dogs on
vaccine-treated fields was significantly higher in each of the
years tested, suggesting that an SPV can protect prairie dogs
from sylvatic plague (Rocke et al. 2017). In a separate 3-year
study, bait uptake of the SPV vaccine was as high as 70% over
58 plots of land. Interestingly, heavier animals exhibited increased bait uptake, and baiting later in the growing season
influenced bait uptake (Abbott et al. 2018). In parallel, Tripp
et al. (2017) compared the effectiveness of dusting prairie dog
burrows with an insecticide to baiting with an oral SPV. In
two of the three plots evaluated, pesticide dusting and oral
SPV improved prairie dog survival and suggested a method
by which the species can be protected from collapse due to
plague-induced mortality (Tripp et al. 2017). Additionally,
Bron et al. (2018) sought to evaluate the impact of a SPV on
non-target rodents over a 3-year period. Although targeting
protection in prairie dogs, 70% of the bait-based vaccine
was consumed by non-target rodents in which no effects were
observed (Bron et al. 2018).
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Future considerations
Generally, it is believed that live-attenuated vaccines confer
the highest degree of protection, generate robust humoral and
cell-mediated responses, and typically result in long-term or
life-long immunity (Slifka and Amanna 2014; US Department
of Health and Human Services n.d.). However, the challenge
associated with live-attenuated vaccines is the threat of a lowfrequency reversion event restoring full virulence, which can
now be circumvented by the development of new generation
designer vaccines.
Interestingly, some unintended pathologies could be rooted
in host genetics rather than reversion of the attenuated Y. pestis
strain. In one such example, a researcher died following exposure to a laboratory nonpigmented (pgm−), attenuated mutant UC91309 Y. pestis strain (unable to produce the
yersiniabactin siderophore required for iron acquisition). The
patient was found to have been compromised by the inherited
genetic malady hemochromatosis, resulting in increased iron
within tissues (Frank et al. 2011). In fact, increased iron presence within host tissues was shown to complement Y. pestis
pgm− attenuated strains in a murine model, and vaccination
using a subunit vaccine was sufficient to achieve protection
upon challenge (Quenee et al. 2012). Furthermore, in a
Y. pestis EV76 murine vaccine study, mobilized ironregulating factors supported vaccine efficacy. More specifically, hemopexin (a host heme binding protein) and transferrin (a
host iron-binding protein) demonstrated anti-bacterial properties in the serum of EV76-immunized mice shortly following
the immunization (Zauberman et al. 2017). Based on those
findings, patients should be pre-screened, and subunit vaccines should be offered, if available, to avoid host factors
complementing live-attenuated vaccine strains.
Subunit vaccine efforts tend to favor F1, LcrV, or combinations thereof; however, screening for novel candidates is
ongoing. In one such effort, over 4000 Y. pestis proteins were
screened computationally and experimentally for the ability to
elicit a cell-mediated response by CD8+ T cells. Ultimately,
178 unique CD8+ T cell epitopes, derived from 113 Y. pestis
proteins, were identified and could be exploited as novel antigens in subunit vaccine development (Zvi et al. 2017).
Additionally, novel clustered regularly interspaced short palindromic repeat interference (CRISPRi) techniques allow reversible characterization of virulence potential of these novel
gene candidates (Wang et al. 2019), which could be exploited
as future vaccine targets.
In the event of a widespread bio-attack, attention has centered on post-exposure antibiotic treatment. However, as mentioned earlier, drug-resistant strains are naturally occurring;
moreover, Y. pestis could be engineered as a multiple-drugresistant weapon (Rosenzweig et al. 2011). As a result, a
mouse model was employed to evaluate the efficacy of a combined post-exposure vaccination followed by antibiotic
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treatment with a second-line chemotherapeutic. More specifically, a live-attenuated EV76 immunization was paired with a
lethal pneumonic challenge and subsequent antibiotic treatment (with a second-line chemotherapeutic); the vaccine and
antibiotic treatment worked synergistically to arrest disease
progression and lessen morbidity (Zauberman et al. 2019).
With regard to Y. pestis, the reemerging plague pathogen
that could become weaponized; novel approaches and creative
strategies need to be applied and translated into viable prophylactic and post-exposure treatments. A vaccine that is well
tolerated with high efficacy and has the ability to promote
cell-mediated and humoral responses is the plague research
community’s top priority. While some progress has been
made on live-attenuated candidates, subunit vaccines still appear to be the favored approach in filling the plague vaccine
void. The COVID-19 pandemic prompted an unprecedentedly
short turn around on two approved mRNA vaccine deliverables, and two adenovirus-based vaccines. With renewed
awareness of the seriousness global pandemics can pose to
human health and economic stability, perhaps approval of a
novel plague vaccine is adequately motivated. Importantly, a
combinatorial approach of Ad5-YFV vaccine followed by a
booster of live-attenuated LMA or LMP mutant or vice versa
could be highly advantageous for preventative and reactive
scenarios, as well as more effective possibly due to differing
mechanisms of protection provided by these two vaccines.
Furthermore, both vaccines can be administered by the intranasal route, avoiding the use of needles. Such studies are being conducted in our laboratory.
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